Rimonabant - Acomplia


Item Name- Price
Rimonabant 20 mg - Acomplia by Sanofi Aventis

Rimonabant 20 mg - Acomplia by Sanofi Aventis

Acomplia - Rimonabant by Sanofi Aventis ONE ORDER UNIT INCLUDES: 28 tablets, each containing 20 mg mg PER TAB: 20 mg TOTAL TABS PER ONE ORDER UNIT:...
EUR 439.00
EUR 369.00
Save: 16% off

... more info
 Out of Stock 


Zimulti Profile:

Rimonabant is used in the treatment of obesity and related conditions by selectively blocking CB1 receptors found in the brain and in peripheral organs important in glucose and lipid (or fat) metabolism, including adipose tissue, the liver, gastrointestinal tract and muscle. It switches off the same brain circuits that make people hungry when they smoke cannabis. Acomplia has also been shown to help in smoking cessation.

Zimulti has been studied by Sanofi-Aventis as an aid to smoking cessation based on studies for up to one year in over 6,500 smokers motivated to quit smoking.

Zimulti Dosing:

Use Rimonabant as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Acomplia usage is one 20 mg tablet every day.

Ask your health care provider any questions you may have about how to use Acomplia.

Missed dose of Zimulti:

If you are using Acomplia regularly and you miss a dose, use it as soon as possible. Then use any remaining doses for that day at regularly spaced intervals. Do not double doses.

Storage - To store Zimulti:

  • Keep out of the reach of children.
  • Store away from heat and direct light.
  • Do not store in the bathroom, near the kitchen sink, or in other damp places. Heat or moisture may cause the medicine to break down.
  • Keep the medicine from freezing. Do not refrigerate.
  • Do not keep outdated medicine or medicine no longer needed. Be sure that any discarded medicine is out of the reach of children.

Zimulti Side effects:

Side effects in the trial on Acomplia in obesity were vomiting and nausea, forcing about 19 percent of patients to leave the trial versus 13 percent of those who took placebo.

Shortly after market introduction, press reports and independent studies suggest that side-effects occur stronger and more commonly than shown by the manufacturer in their clinical studies. Reports of severe depression are frequent. This is deemed to result from the drug's being active in the central nervous system, an area of human physiology so complex that the effects of a drug are extremely difficult to predict or anticipate.

Because the drug has the opposite effects of cannabinoid receptor agonists such as tetrahydrocannabinol (THC, one of the substances found in marijuana), which is neuroprotective against excitotoxicity, it can be theorized that Rimonabant promotes the development of neurodegenerative diseases of the central nervous system such as Multiple sclerosis, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Huntington's disease in persons that are susceptible. The reported development of previously clinically-silent multiple sclerosis in one patient taking Rimonabant suggests that any patients with an underlying neurological condition should not take Rimonabant, given the neuroprotective role of the endocannabinoid system in many experimental paradigms of neurological disease.

Monthly Specials For November

Rimonabant 20 mg - Acomplia by Sanofi AventisRimonabant 20 mg - Acomplia by Sanofi Aventis
EUR 439.00
EUR 369.00
Save: 16% off

Copyright © 2017 EuroBolic.com
EuroBolic.com, EuroBolic.org, EuroBolic.net, EuroBolic.su and EuroBolic.ru are divisions of EuroBolic.com.